Miki Hirokazu, Tokuhara Katsuji, Oishi Masaharu, Nakatake Richi, Tanaka Yoshito, Kaibori Masaki, Nishizawa Mikio, Okumura Tadayoshi, Kon Masanori
Department of Surgery, Kansai Medical University, Hirakata, Osaka, Japan.
Department of Biomedical Sciences, College of Life Sciences Ritsumeikan University, Kusatsu, Shiga, Japan.
JPEN J Parenter Enteral Nutr. 2016 Sep;40(7):1033-41. doi: 10.1177/0148607115575035. Epub 2015 Mar 9.
Japanese herbal medicine, Kampo saireito, is used for treatments in patients with digestive diseases, including chronic hepatitis and cirrhosis. However, few studies demonstrate scientific evidence for liver-protective effects of saireito. In inflamed liver, proinflammatory cytokines such as tumor necrosis factor (TNF)-α and interleukin (IL)-1β stimulate the induction of inducible nitric oxide synthase (iNOS) and nitric oxide (NO) production. Excessive levels of NO synthesized by iNOS have been implicated as one of the factors in liver injury, so it is essential to reduce the induction of iNOS for the prevention of liver injury. In this study, we examined IL-1β-stimulated hepatocytes as a simple "in vitro injury model" to investigate liver-protective effects of saireito.
Primary cultured rat hepatocytes were treated with IL-1β in the presence or absence of saireito. The induction of NO production and iNOS and its signaling pathway were analyzed.
Saireito inhibited the production of NO dose and time dependently and reduced the expression of iNOS messenger RNA (mRNA) and its protein. Saireito had no effect on IκB degradation but inhibited the translocation of nuclear factor (NF)-κB to the nucleus and its DNA binding. Saireito also inhibited the activation of Akt, resulting in the reduction of type I IL-1 receptor (IL-1RI) mRNA and protein expression.
These findings demonstrate that saireito suppresses iNOS gene expression through the inhibition of NF-κB and IL-1RI-dependent pathways, leading to the reduction of NO production. Saireito may have therapeutic potential for organ injuries, including liver.
日本草药柴苓汤用于治疗包括慢性肝炎和肝硬化在内的消化系统疾病患者。然而,很少有研究能证明柴苓汤具有肝脏保护作用的科学证据。在炎症性肝脏中,肿瘤坏死因子(TNF)-α和白细胞介素(IL)-1β等促炎细胞因子会刺激诱导型一氧化氮合酶(iNOS)的诱导和一氧化氮(NO)的产生。iNOS合成的过量NO已被认为是肝损伤的因素之一,因此减少iNOS的诱导对于预防肝损伤至关重要。在本研究中,我们以白细胞介素-1β刺激的肝细胞作为简单的“体外损伤模型”,来研究柴苓汤的肝脏保护作用。
在有或没有柴苓汤存在的情况下,用白细胞介素-1β处理原代培养的大鼠肝细胞。分析NO产生、iNOS及其信号通路的诱导情况。
柴苓汤剂量和时间依赖性地抑制NO的产生,并降低iNOS信使核糖核酸(mRNA)及其蛋白质的表达。柴苓汤对IκB降解没有影响,但抑制核因子(NF)-κB向细胞核的转位及其与DNA的结合。柴苓汤还抑制Akt的激活,导致I型白细胞介素-1受体(IL-1RI)mRNA和蛋白质表达的减少。
这些发现表明,柴苓汤通过抑制NF-κB和IL-1RI依赖性途径来抑制iNOS基因表达,从而减少NO的产生。柴苓汤可能对包括肝脏在内的器官损伤具有治疗潜力。